サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：胃がん治療市場 - 世界の産業規模、シェア、動向、機会、予測、2018-2028年：治療タイプ別、がんタイプ別、投与経路別、薬効分類別、流通チャネル別、地域別セグメント、競合
市場調査レポート
商品コード
1255250

胃がん治療市場 - 世界の産業規模、シェア、動向、機会、予測、2018-2028年：治療タイプ別、がんタイプ別、投与経路別、薬効分類別、流通チャネル別、地域別セグメント、競合

Stomach Cancer Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Treatment Type, By Cancer Type, By Route of Administration, By Drug Class, By Distribution Channel, By Region and Competition
出版日: | 発行: TechSci Research | ページ情報: 英文 112 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

胃がん治療市場 - 世界の産業規模、シェア、動向、機会、予測、2018-2028年：治療タイプ別、がんタイプ別、投与経路別、薬効分類別、流通チャネル別、地域別セグメント、競合
出版日: 2023年04月01日
発行: TechSci Research
ページ情報: 英文 112 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の胃がん治療市場は、予測期間中に目覚ましい成長を遂げると予想されています。

これは、胃がんを治療するための新規薬剤や治療法の開発が進んでいることに起因しています。さらに、痛みの少ない低コスト治療への需要の高まりと、がん治療に対する有利な償還シナリオが、世界のさまざまな地域で胃がん治療の成長を大きく後押ししています。さらに、胃がんなどの慢性疾患にかかりやすい高齢化社会の到来は、さまざまながん治療に対する需要を高め、2028年までの市場成長を加速させると予想されます。また、新しい治療法の利点に関する意識の高まりや、世界のがん疾患への支出の増加は、予測期間中の胃がん治療市場をさらにサポートすると予想されます。

胃がんの有病率の増加

世界的に腺がん、リンパ腫、消化管間質腫瘍の発生が増加していることが、予測期間中の市場成長を後押ししています。同様に、高齢化人口の増加は、特に高齢男性の間で、世界で最も一般的な致命的ながんの一つである胃がんのような慢性疾患にかかりやすくなっています。これは、予測期間中の市場成長を後押しすると予想されます。米国国立がん研究所によると、2022年には米国で新たに26,380人の胃がん患者が発生し、11,090人が死亡すると推定されています。新興諸国では、胃がんは女性よりも男性の方が多く診断されますが、これは女性が男性にはない特定の保護遺伝子のコピーを細胞内に余分に持っているためです。この地域における胃がんの有病率の増加は、患者を治療するための効果的な治療法を要求しており、その結果、予測期間中の市場成長を促進すると予想されます。例えば、カナダがん協会が発表した2021年の統計によると、4,000人のカナダ人が胃がんに罹患しています。

ヘルスケア産業における発展の高まり

胃がんの有病率の増加とともに、新たに開発された薬剤の政府からの承認が増加しているため、胃がん市場は長年にわたって有利な成長見通しを生み出すと期待されています。研究開発活動は、新薬や治療法の開発において大きな役割を担っています。例えば、台湾の研究チームは最近、2つの胃がんバイオマーカーを発表しました。この進歩は、胃がん市場に顕著な成長見通しをもたらし、市場成長を後押しする可能性があります。同様に、経口薬も、ほとんどの製品がカプセルや錠剤で提供されており、投与経路として非常に現実的であることから、予測期間中に市場成長を後押しすると予想されます。国民の健康意識の高まりは、胃がん治療市場の成長を後押しすると期待されています。胃がん治療のための革新的な治療法の発売は、同時に市場を強化すると予想されます。さまざまな研究者や政府機関が、患者だけでなく市場にも利益をもたらす新薬の開発に投資しており、これが市場にさらなる機会を生み出しています。2022年には、米国でこの病気による死亡が11,090人（男性6,690人、女性4,400人）発生すると推定されています。2020年には、世界中で推定768,793人が胃がんにより死亡しています。

最近の開発状況

例えば、2021年4月、米国FDAは、Bristol-Myers Squibb Companyの製品「Opdivo」を、フルオロピリミジンおよびプラチナを含む化学療法との併用で、転移性胃がんの治療として承認しました。

利用可能なカスタマイズ

与えられた市場データをもとに、TechSci Researchは企業の特定のニーズに応じてカスタマイズを提供します。本レポートでは、以下のカスタマイズが可能です。

企業情報

  • 追加市場プレイヤー（最大5社）の詳細分析およびプロファイリング

目次

第1章 概要

  • 市場の定義
  • 市場の範囲
    • 対象市場
    • 研究対象年
    • 主な市場セグメンテーション

第2章 調査手法

  • 調査目的
  • ベースライン調査手法
  • 主要産業パートナー
  • 主な協会と二次情報
  • 調査手法
  • データの三角測量と検証
  • 前提条件と限界

第3章 エグゼクティブサマリー

  • 市場概要
  • 主要市場セグメンテーションの概要
  • 主要市場プレイヤーの概要
  • 主要地域/国の概要
  • 市場促進要因・課題・動向

第4章 VOC (顧客の声)

第5章 胃がん治療薬の世界市場展望

  • 市場規模・予測
    • 数量別
  • 市場シェアと予測
    • 治療タイプ別（免疫療法、標的療法、化学療法、放射線療法、その他）
    • がんタイプ別（胃がん／胃食道接合部がん／胃腸間質性腫瘍）
    • 投与経路別（経口剤／注射剤）
    • 薬剤クラス別（PD-1/PD-L1阻害剤、HER2拮抗剤、VEGFR2拮抗剤、その他）
    • 流通チャネル別（病院薬局、専門薬局、その他）
    • 地域別
    • 企業別（2022年）
  • マーケットマップ
    • 治療タイプ別
    • がんタイプ別
    • 投与経路別
    • 薬効分類別
    • 流通チャネル別
    • 地域別

第6章 北米の胃がん治療市場の展望

  • 市場規模・予測
    • 数量別
  • 市場シェアと予測
    • 治療タイプ別
    • がんタイプ別
    • 投与経路別
    • 薬効分類別
    • 流通チャネル別
    • 国別
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の胃がん治療市場の展望

  • 市場規模・予測
    • 数量別
  • 市場シェアと予測
    • 治療タイプ別
    • がんタイプ別
    • 投与経路別
    • 薬効分類別
    • 流通チャネル別
    • 国別
  • 欧州：国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋の胃がん治療市場の展望

  • 市場規模・予測
    • 数量別
  • 市場シェアと予測
    • 治療タイプ別
    • がんタイプ別
    • 投与経路別
    • 薬効分類別
    • 流通チャネル別
    • 国別
  • アジア太平洋地域の：国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米の胃がん治療市場の展望

  • 市場規模・予測
    • 数量別
  • 市場シェアと予測
    • 治療タイプ別
    • がんタイプ別
    • 投与経路別
    • 薬効分類別
    • 流通チャネル別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの胃がん治療市場の展望

  • 市場規模・予測
    • 数量別
  • 市場シェアと予測
    • 治療タイプ別
    • がんタイプ別
    • 投与経路別
    • 薬効分類別
    • 流通チャネル別
    • 国別
  • MEA：国別分析
    • 南アフリカ胃がん治療
    • サウジアラビアの胃がん治療
    • UAE胃がん治療
    • トルコの胃がん治療
    • エジプト胃がん治療

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場の動向と開拓

  • 最近の動向
  • M&A（合併・買収
  • 製品発表会

第13章 競合情勢

  • Business Overview
  • Product Offerings
  • Recent Developments
  • Financials（As Reported）
  • Key Personnel
  • SWOT Analysis
    • Pfizer, Inc.
    • Novartis International AG
    • Eli Lilly and Company
    • Bristol Myers Squibb Company
    • Teva Pharmaceutical Industries AG
    • F. Hoffmann La Roche AG
    • Mylan N.V.
    • Celltrion Healthcare Co., Ltd
    • Merck & Co., Inc.
    • Teva Pharmaceutical Industries Ltd.

第14章 戦略的な提言

目次
Product Code: 14348

The global stomach cancer treatment market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the growing development of novel drugs and therapies for treating stomach cancer. Additionally, growing demand for painless low-cost treatment and favorable reimbursement scenarios for the treatment of cancer have significantly increased the growth of stomach cancer treatment across different parts of the globe. Additionally, the growing aging population across the globe, which is more prone to different kinds of chronic diseases like stomach cancer, is further expected to increase the demand for different cancer therapies, thereby fuelling market growth through 2028. Besides, growing awareness about the benefits of new therapies, with increasing expenditure on cancer diseases worldwide, is further expected to support the stomach cancer treatment market during the forecast period.

Growing Prevalence of Stomach Cancer

Increasing incidences of adenocarcinoma, lymphoma, and gastrointestinal stromal tumors across the world are driving market growth during the forecast period. Similarly, the rising aging population is susceptible to chronic diseases like stomach cancer, which is one of the most common deadly cancers worldwide, especially among older males. This is expected to boost market growth in the forecast period. According to National Cancer Institute, in 2022, 26,380 new stomach cancer cases and 11,090 deaths are estimated in the United States. In developing countries, stomach cancer is more diagnosed in males than females because females carry an extra copy of certain protective genes in their cells that men don't have. The increasing prevalence of gastric cancer in the region is demanding effective therapies for treating patients, which, in turn, is expected to propel the market growth during the forecast period. For instance, according to the 2021 statistics published by the Canadian Cancer Society, 4,000 Canadians were affected by gastric cancer.

Growing Development In Healthcare Industry

Increasing approval of newly developed drugs from the government, along with the growing prevalence of stomach cancer, is expected to create a lucrative growth prospect for the stomach cancer market over the years. Research & Development activities play a major role in developing novel drugs and therapies. For instance, a research team from Taiwan has recently launched two gastric cancer biomarkers. This advancement may bring remarkable growth prospects for the stomach cancer market, thereby boosting the market growth. Similarly, oral drugs are expected to boost market growth during the forecast period as most products are available in capsules and tablets, making it a very feasible route of administration. Growing health awareness among the population is expected to boost the stomach cancer treatment market growth. The innovative therapy launches for treating gastric cancer are expected to enhance the market simultaneously. Different researchers and government organizations are investing in the development of novel drugs that benefit the market as well as the patient; this creates more opportunities in the market. It is estimated that 11,090 deaths (6,690 men and 4,400 women) from this disease will occur in the United States in 2022. In 2020, an estimated 768,793 people died from stomach cancer worldwide.

Market Segmentation

The global stomach cancer treatment market can be segmented by treatment type, cancer type, route of administration, drug class, distribution channel, and by region. Based on treatment type, the market can be segmented into Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy, and Others. Based on cancer type, the market can be differentiated into Gastric Cancer/Gastroesophageal Junction Cancer v/s Gastrointestinal Stromal Tumors. Based on the route of administration, the market can be divided into Oral v/s Injectables. Based on drug class, the market can be segmented into PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, and Others. Based on distribution channels, the market can be grouped into Hospital Pharmacies, Specialty Pharmacies, and Others. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, the United States dominated the global stomach cancer treatment market on account of the growing demand for advanced cancer therapy in the country.

Market Players

Pfizer, Inc., Novartis International AG, Eli Lilly and Company, Bristol Myers Squibb Company, Teva Pharmaceutical Industries AG, F. Hoffmann La Roche AG, Mylan N.V., Celltrion Healthcare Co., Ltd, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd. are some of the leading players operating in the Global Stomach Cancer Treatment Market.

Recent Developments

For instance, in April 2021, the U.S. FDA approved Bristol-Myers Squibb Company's product Opdivo in combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of metastatic gastric cancer.

Report Scope

In this report, global stomach cancer treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Stomach Cancer Treatment Market, By Treatment Type:

  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy
  • Radiation Therapy
  • Others

Stomach Cancer Treatment Market, By Cancer Type:

  • Gastric Cancer/Gastroesophageal Junction Cancer
  • Gastrointestinal Stromal Tumors

Stomach Cancer Treatment Market, By Route of Administration:

  • Oral
  • Injectables

Stomach Cancer Treatment Market, By Drug Class:

  • PD-1/PD-L1 Inhibitors
  • HER2 Antagonists
  • VEGFR2 Antagonists
  • Others

Stomach Cancer Treatment Market, By Distribution Channel:

  • Hospital Pharmacies
  • Specialty Pharmacies
  • Others

Stomach Cancer Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Stomach Cancer Treatment Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Stomach Cancer Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy, Others)
    • 5.2.2. By Cancer Type (Gastric Cancer/Gastroesophageal Junction Cancer v/s Gastrointestinal Stromal Tumors)
    • 5.2.3. By Route of Administration (Oral v/s Injectables)
    • 5.2.4. By Drug Class (PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Others)
    • 5.2.5. By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2022)
  • 5.3. Market Map
    • 5.3.1. By Treatment Type
    • 5.3.2. By Cancer Type
    • 5.3.3. By Route of Administration
    • 5.3.4. By Drug Class
    • 5.3.5. By Distribution Channel
    • 5.3.6. By Region

6. North America Stomach Cancer Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By Cancer Type
    • 6.2.3. By Route of Administration
    • 6.2.4. By Drug Class
    • 6.2.5. By Distribution Channel
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Stomach Cancer Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By Cancer Type
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By Drug Class
        • 6.3.1.2.5. By Distribution Channel
    • 6.3.2. Canada Stomach Cancer Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By Cancer Type
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By Drug Class
        • 6.3.2.2.5. By Distribution Channel
    • 6.3.3. Mexico Stomach Cancer Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By Cancer Type
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By Drug Class
        • 6.3.3.2.5. By Distribution Channel

7. Europe Stomach Cancer Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By Cancer Type
    • 7.2.3. By Route of Administration
    • 7.2.4. By Drug Class
    • 7.2.5. By Distribution Channel
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Stomach Cancer Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By Cancer Type
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Drug Class
        • 7.3.1.2.5. By Distribution Channel
    • 7.3.2. Germany Stomach Cancer Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By Cancer Type
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Drug Class
        • 7.3.2.2.5. By Distribution Channel
    • 7.3.3. United Kingdom Stomach Cancer Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By Cancer Type
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Drug Class
        • 7.3.3.2.5. By Distribution Channel
    • 7.3.4. Italy Stomach Cancer Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By Cancer Type
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By Drug Class
        • 7.3.4.2.5. By Distribution Channel
    • 7.3.5. Spain Stomach Cancer Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By Cancer Type
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By Drug Class
        • 7.3.5.2.5. By Distribution Channel

8. Asia-Pacific Stomach Cancer Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By Cancer Type
    • 8.2.3. By Route of Administration
    • 8.2.4. By Drug Class
    • 8.2.5. By Distribution Channel
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Stomach Cancer Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By Cancer Type
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Drug Class
        • 8.3.1.2.5. By Distribution Channel
    • 8.3.2. India Stomach Cancer Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By Cancer Type
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Drug Class
        • 8.3.2.2.5. By Distribution Channel
    • 8.3.3. Japan Stomach Cancer Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By Cancer Type
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Drug Class
        • 8.3.3.2.5. By Distribution Channel
    • 8.3.4. South Korea Stomach Cancer Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By Cancer Type
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Drug Class
        • 8.3.4.2.5. By Distribution Channel
    • 8.3.5. Australia Stomach Cancer Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By Cancer Type
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Drug Class
        • 8.3.5.2.5. By Distribution Channel

9. South America Stomach Cancer Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By Cancer Type
    • 9.2.3. By Route of Administration
    • 9.2.4. By Drug Class
    • 9.2.5. By Distribution Channel
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Stomach Cancer Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By Cancer Type
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Drug Class
        • 9.3.1.2.5. By Distribution Channel
    • 9.3.2. Argentina Stomach Cancer Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By Cancer Type
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Drug Class
        • 9.3.2.2.5. By Distribution Channel
    • 9.3.3. Colombia Stomach Cancer Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By Cancer Type
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Drug Class
        • 9.3.3.2.5. By Distribution Channel

10. Middle East and Africa Stomach Cancer Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By Cancer Type
    • 10.2.3. By Route of Administration
    • 10.2.4. By Drug Class
    • 10.2.5. By Distribution Channel
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Stomach Cancer Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By Cancer Type
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Drug Class
        • 10.3.1.2.5. By Distribution Channel
    • 10.3.2. Saudi Arabia Stomach Cancer Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By Cancer Type
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Drug Class
        • 10.3.2.2.5. By Distribution Channel
    • 10.3.3. UAE Stomach Cancer Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By Cancer Type
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Drug Class
        • 10.3.3.2.5. By Distribution Channel
    • 10.3.4. Turkey Stomach Cancer Treatment Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Treatment Type
        • 10.3.4.2.2. By Cancer Type
        • 10.3.4.2.3. By Route of Administration
        • 10.3.4.2.4. By Drug Class
        • 10.3.4.2.5. By Distribution Channel
    • 10.3.5. Egypt Stomach Cancer Treatment Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Treatment Type
        • 10.3.5.2.2. By Cancer Type
        • 10.3.5.2.3. By Route of Administration
        • 10.3.5.2.4. By Drug Class
        • 10.3.5.2.5. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Competitive Landscape

  • 13.1. Business Overview
  • 13.2. Product Offerings
  • 13.3. Recent Developments
  • 13.4. Financials (As Reported)
  • 13.5. Key Personnel
  • 13.6. SWOT Analysis
    • 13.6.1. Pfizer, Inc.
    • 13.6.2. Novartis International AG
    • 13.6.3. Eli Lilly and Company
    • 13.6.4. Bristol Myers Squibb Company
    • 13.6.5. Teva Pharmaceutical Industries AG
    • 13.6.6. F. Hoffmann La Roche AG
    • 13.6.7. Mylan N.V.
    • 13.6.8. Celltrion Healthcare Co., Ltd
    • 13.6.9. Merck & Co., Inc.
    • 13.6.10. Teva Pharmaceutical Industries Ltd.

14. Strategic Recommendations